IsoPlexis (NASDAQ:ISO – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its peers? We will compare IsoPlexis to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Risk and Volatility
IsoPlexis has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, IsoPlexis’ peers have a beta of 1.04, indicating that their average share price is 4% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for IsoPlexis and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IsoPlexis | 0 | 2 | 0 | 0 | 2.00 |
| IsoPlexis Competitors | 193 | 1105 | 1712 | 59 | 2.53 |
Valuation and Earnings
This table compares IsoPlexis and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| IsoPlexis | $16.76 million | -$106.00 million | -0.28 |
| IsoPlexis Competitors | $1.07 billion | -$256.75 million | 5.52 |
IsoPlexis’ peers have higher revenue, but lower earnings than IsoPlexis. IsoPlexis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares IsoPlexis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IsoPlexis | -632.41% | -127.86% | -71.41% |
| IsoPlexis Competitors | -273.31% | 238.74% | -17.34% |
Insider & Institutional Ownership
44.9% of IsoPlexis shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.4% of IsoPlexis shares are owned by company insiders. Comparatively, 16.4% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
IsoPlexis peers beat IsoPlexis on 10 of the 13 factors compared.
About IsoPlexis
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.
